VLDLR
Basic information
Region (hg38): 9:2621182-2660056
Links
Phenotypes
GenCC
Source:
- cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1 (Definitive), mode of inheritance: AR
- cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1 (Strong), mode of inheritance: AR
- cerebellar ataxia, intellectual disability, and dysequilibrium (Supportive), mode of inheritance: AR
- cerebellar ataxia, intellectual disability, and dysequilibrium syndrome 1 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Cerebellar hypoplasia, impaired intellectual development, and dysequilibrium syndrome 1 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 16080122; 18043714; 18326629; 18364738; 20082205 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (610 variants)
- Inborn_genetic_diseases (119 variants)
- Cerebellar_ataxia,_intellectual_disability,_and_dysequilibrium_syndrome_1 (106 variants)
- not_specified (61 variants)
- Congenital_cerebellar_hypoplasia (30 variants)
- VLDLR-related_disorder (23 variants)
- Intellectual_disability (3 variants)
- Dysequilibrium_syndrome (2 variants)
- See_cases (2 variants)
- Abnormality_of_the_nervous_system (1 variants)
- Cerebellar_hypoplasia (1 variants)
- Microcephaly (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VLDLR gene is commonly pathogenic or not. These statistics are base on transcript: NM_000003383.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 7 | 240 | 1 | 248 | ||
| missense | 2 | 3 | 186 | 16 | 207 | |
| nonsense | 18 | 5 | 23 | |||
| start loss | 1 | 1 | ||||
| frameshift | 11 | 3 | 1 | 15 | ||
| splice donor/acceptor (+/-2bp) | 1 | 18 | 4 | 23 | ||
| Total | 32 | 30 | 198 | 256 | 1 |
Highest pathogenic variant AF is 0.000016108486
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| VLDLR | protein_coding | protein_coding | ENST00000382100 | 19 | 38220 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 125698 | 0 | 50 | 125748 | 0.000199 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -1.12 | 534 | 466 | 1.15 | 0.0000262 | 5813 |
| Missense in Polyphen | 161 | 186.32 | 0.86411 | 2403 | ||
| Synonymous | -1.74 | 203 | 174 | 1.17 | 0.0000107 | 1567 |
| Loss of Function | 3.17 | 26 | 50.3 | 0.517 | 0.00000323 | 557 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000522 | 0.000521 |
| Ashkenazi Jewish | 0.000893 | 0.000893 |
| East Asian | 0.000326 | 0.000326 |
| Finnish | 0.0000462 | 0.0000462 |
| European (Non-Finnish) | 0.000202 | 0.000202 |
| Middle Eastern | 0.000326 | 0.000326 |
| South Asian | 0.0000653 | 0.0000653 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation (By similarity). {ECO:0000250}.;
- Disease
- DISEASE: Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 (CAMRQ1) [MIM:224050]: A congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation, cerebellar hypoplasia and mild cerebral gyral simplification. Additional features include short stature, strabismus, pes planus and, rarely, seizures. {ECO:0000269|PubMed:16080122}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Developmental Biology;VLDL clearance;VLDLR internalisation and degradation;Plasma lipoprotein clearance;Transport of small molecules;Plasma lipoprotein assembly, remodeling, and clearance;Axon guidance;Reelin signalling pathway;Reelin signaling pathway;Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling;Lissencephaly gene (LIS1) in neuronal migration and development
(Consensus)
Recessive Scores
- pRec
- 0.490
Intolerance Scores
- loftool
- 0.0391
- rvis_EVS
- -1.06
- rvis_percentile_EVS
- 7.55
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.690
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;lipid transport;receptor-mediated endocytosis;signal transduction;nervous system development;axon guidance;memory;cholesterol metabolic process;ventral spinal cord development;low-density lipoprotein particle receptor catabolic process;glycoprotein transport;very-low-density lipoprotein particle clearance;reelin-mediated signaling pathway;positive regulation of protein kinase activity;dendrite morphogenesis;positive regulation of dendrite development
- Cellular component
- lysosomal membrane;plasma membrane;clathrin-coated pit;membrane;integral component of membrane;very-low-density lipoprotein particle;receptor complex
- Molecular function
- low-density lipoprotein particle receptor activity;calcium ion binding;protein binding;very-low-density lipoprotein particle receptor activity;apolipoprotein binding;very-low-density lipoprotein particle binding;glycoprotein transporter activity;reelin receptor activity;calcium-dependent protein binding